Global surgical robotics leader Intuitive Surgical (ISRG.US) released its third-quarter 2026 earnings report on October 20, Eastern Time, and JPMorgan issued a research report on the same day, maintaining an "Overweight" rating on the stock.
Zhitong Finance reports that Intuitive Surgical (ISRG.US), the global leader in surgical robotics, released its third-quarter 2026 results on October 20 Eastern Time. On the same day, JPMorgan issued a research report, maintaining an "Overweight" rating on the stock and raising the price target to $475. The firm noted that, in the rapidly growing soft-tissue robotics market—where penetration remains low—Intuitive Surgical is the company best positioned to capitalize on opportunities. Data show that the company's revenue, profit, and gross margin all significantly exceeded market expectations; however, its core metric—the number of U.S. procedures—only met consensus estimates, falling short of buy-side institutions' more optimistic projections, putting downward pressure on the stock in after-hours trading following the earnings release.
Profits have soared across the board, with hardware build performance standing out.
According to the financial report, the company's total revenue for the third quarter reached $3.049 billion. Revenue from surgical systems amounted to $769 million, up 30% year over year. Global installations of the da Vinci system totaled 546, a 28% increase compared with the same period last year, with 315 units of the next‑generation da Vinci Xi model installed—significantly exceeding prior institutional forecasts. Both U.S. and international markets posted stronger-than-expected growth in installations, and progress in expanding the ambulatory surgery center (ASC) channel was particularly notable.
Recurring revenue streams, including consumables and services, also delivered strong results. Revenue from instruments and consumables (I&A) reached $1.8 billion, up 18% year over year, while service revenue totaled $482 million, a 22% increase compared with the prior year. On the profitability front, adjusted EPS came in at $3.00, $0.36 above market expectations, representing a 14% rise; gross margin expanded to 69.9%, and operating margin exceeded estimates by 230 basis points. During the quarter, the company completed approximately $3.0 billion in share repurchases and raised its full-year gross margin guidance to 68.7%–69.3%. However, GAAP EPS was only $1.49, weighed down by a one-time pre‑tax charge of $450 million related to an antitrust settlement.
U.S. surgical volume fell short of optimistic expectations, with overseas markets emerging as the growth engine.
Surgical volume is the key KPI that underpins Intuitive Surgical's valuation. Global da Vinci procedure volume grew 14% year over year, but U.S.‑based procedures expanded by only 10%, matching market expectations while falling short of buy-side analysts' more optimistic forecasts by 1–2 percentage points—this discrepancy has been a major drag on the stock price. Affected by a high base effect, U.S. equipment utilization declined month over month, and the bariatric surgery segment posted a low‑double-digit decline.
By contrast, overseas markets delivered robust performance, with da Vinci surgical procedures up 20% year over year. Growth was broad-based across Europe and Asia, with India posting a remarkable 42% increase, while Japan saw accelerated momentum for the second consecutive quarter, supported by improved reimbursement policies. In China, growth matched the company's overall average, but remained constrained by a weak capital‑equipment installation environment. Management has narrowed its full-year guidance for da Vinci procedure growth to 14%–15%.
The impact of the price adjustment is manageable, and institutions are recommending a pullback‑based buying strategy.
The company has introduced a new pricing scheme for extending the use of its medical devices, coupled with price reductions in the Chinese market. Once the policy is fully implemented, revenue from single-use surgical consumables is expected to face pressure of 3–5%, a magnitude lower than the 7% decline seen in 2020. The price adjustments will be phased in, with their full impact gradually realized by 2027. Drawing on historical experience, management believes that price cuts could unlock demand elasticity, while cost reductions should help offset margin pressures.
JPMorgan pointed out that 74% of the stock's volatility stems from the company's own fundamentals. Although the financial report is generally of high quality, the stock price had already been boosted by optimistic third-party data in the earlier period, and a reasonable pullback of 3–5% is expected. If the opening price falls further by about 7%, that would present a favorable buying opportunity. In the long term, the penetration rate of soft-tissue surgical robots remains low; coupled with new indications and expansion into overseas markets, the company's growth potential remains substantial. Risks are concentrated in new-product R&D, competitive pressures, and product safety incidents.
As of the close on October 20, Intuitive Surgical was trading at $438, with a market capitalization of approximately $158.8 billion, and a 52-week price range of $328.57 to $603.88.